Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474572 | 1.00 | BRD4 (0.38) | BRD4CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4465969 | 0.88 | PSIP1 (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4465966 | 0.88 | PSIP1 (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL4460358 | 0.81 | MAPT (0.43) | KDRGAAMAPT | |
| SCHEMBL4460352 | 0.81 | MAPT (0.43) | KDRGAAMAPT | |
| SCHEMBL4463051 | 0.78 | SMN1; SMN2 (0.36) | GAAMAPT | |
| SCHEMBL4463046 | 0.78 | SMN1; SMN2 (0.36) | GAAMAPT | |
| SCHEMBL4464531 | 0.77 | KDM4A (0.42) | GAAMAPT | |
| SCHEMBL4464526 | 0.77 | KDM4A (0.42) | GAAMAPT | |
| SCHEMBL4459243 | 0.76 | HTR6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | claimed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | claimed |
| US-7550598-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041137-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | BRD4 929/4885CYP1A2 3175/4885CYP3A4 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.